Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats
-
Add time:08/04/2019 Source:sciencedirect.com
The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of RAMOSETRON (cas 132036-88-5), a potent serotonin 3 (5-HT3) receptor antagonist, and other anti-irritable bowel syndrome agents in this model. Rats stressed by a conditioned stress procedure exhibited marked prolongation of freezing time, an index of fear level, and an increase in the frequency of defecation (P < 0.01). A corticotropin-releasing factor (CRF) antagonist, α-helical CRF, inhibited both defecation and freezing behavior, while the antidiarrheal loperamide inhibited defecation only. The 5-HT3 receptor antagonists ramosetron, cilansetron and alosetron also inhibited defecation (ED50 values: 0.012, 0.094, 0.078 mg/kg p.o., respectively) without affecting freezing behavior. Ramosetron showed longer-lasting effect on defecation than cilansetron. Stress also resulted in increases in both proximal and distal colonic transit rates. Ramosetron and other 5-HT3 receptor antagonists at doses inhibiting stress-induced defecation also ameliorated both stress-stimulated colonic transit rates. These results suggest that ramosetron, as well as agents used for the treatment of irritable bowel syndrome with diarrhea, has beneficial effects against emotional stress-induced colonic dysfunction. Furthermore, this emotional stress model may be useful in evaluation of drugs to treat irritable bowel syndrome presenting with diarrhea.
We also recommend Trading Suppliers and Manufacturers of RAMOSETRON (cas 132036-88-5). Pls Click Website Link as below: cas 132036-88-5 suppliers
Prev:Comparison of RAMOSETRON (cas 132036-88-5) with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery
Next:Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) on duodenal acidification-induced gastric hypersensitivity in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) on duodenal acidification-induced gastric hypersensitivity in rats08/05/2019
- Comparison of RAMOSETRON (cas 132036-88-5) with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery08/03/2019
- Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study08/02/2019
- Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial08/01/2019
- RAMOSETRON (cas 132036-88-5) Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women07/31/2019
- RAMOSETRON (cas 132036-88-5) vs. RAMOSETRON (cas 132036-88-5) plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy: Prospective, randomized, and double-blind study07/30/2019
- Effect of RAMOSETRON (cas 132036-88-5) on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea07/29/2019
- Effects of prophylactic RAMOSETRON (cas 132036-88-5) and ondansetron on corrected QT interval during general anesthesia07/28/2019
- Comparison of RAMOSETRON (cas 132036-88-5) With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial07/27/2019


